XCancer

Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer

Description:

The results of previous studies suggest further development of \[18F\]EF5 as a PET tracer for imaging hypoxia. This is a non-randomized prospective study to obtain information on reproducibility of \[18F\]EF5 intratumor distribution using repeated pretreatment PET/CT scans.

Sponsor:

Turku University Hospital

Phase:

Phase 2

Contacts:

Heikki Minn, Professor (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01774760 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

EF5

Isotope(s):
Target(s):
  • Hypoxia
Ligand Class: Small Molecules
Inclusion
  • * Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
  • Primary tumor diameter as determined clinically or from contrast enhanced CT or T1-weighed MRI scan must be at least 15 mm
  • Diagnosis: Histological, cytological and clinical findings are consistent with squamous cell carcinoma of the head and neck
  • Patients with nodal neck metastases of head and neck cancer are eligible
  • Mental status: Patients must be able to understand the meaning of the study
Exclusion
  • * Patient must have no history of serious haematologic, cardiovascular, liver or kidney disease.
  • Patient must have no history of previous chemotherapy or biological therapy or RT for treatment of head and neck cancer.
  • Patients with organ metastases in liver, bone, brain or lung.
  • Patient must not have an uncontrolled serious infection